Market Overview

Sympathy Move: Portola Upgraded After Competitor Reports Sour Data

Sympathy Move: Portola Upgraded After Competitor Reports Sour Data

Portola Pharmaceuticals Inc (NASDAQ: PTLA), a biotech focusing on thrombosis, other hematological disorders and inflammation, received a one-notch upgrade from Credit Suisse. 

The Analyst

Analyst Vamil Divan upgraded Portola from Underperform to Neutral and raised the price target from $28 to $34.

The Thesis

At the European Society of Cardiology meeting, Johnson & Johnson (NYSE: JNJ) and Bayer AG (ADR) (OTC: BAYRY) reported disappointing data for Xarelto, an oral anticoagulant medication tested in an acute medically ill population, Divan said in a Sunday note. (See the analyst's track record here.) 

The negative data from the MARINER study derisks Portola's Bevyxxa by putting out a potentially strong rival in the post-hospital discharge market for the foreseeable future, the analyst said. 

Portola may now have to build the market on its own without any assistance from Johnson & Johnson, Divan said. The adoption rate is likely to be slow, he said. 

Even after according Bevyxxa a 100-percent share, Credit Suisse trimmed its peak sales estimate for Bevyxxa from $550 million to $400 million, citing slower market penetration.

"We still await better commercial execution from the Portola team but are comfortable moving to a Neutral rating and a $34 target price," Divan said. 

Credit Suisse sees further longer-term potential upside if Bevyxxa and Andexxa achieve the level of commercial success the sell-side firm previously believed was possible.

Credit Suisse maintained its 2018 loss per share estimates for Portola and widened its loss estimate for 2019 and 2020.

The Price Action

Portola shares were down 2 percent at $27.60 at the time of publication Monday. 

Related Links:

Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Results

Latest Ratings for PTLA

May 2020Morgan StanleyMaintainsEqual-Weight
Apr 2020RBC CapitalInitiates Coverage OnOutperform
Jan 2020OppenheimerDowngradesOutperformPerform

View More Analyst Ratings for PTLA
View the Latest Analyst Ratings


Related Articles (PTLA)

View Comments and Join the Discussion!

Posted-In: Credit Suisse Vamil DivanAnalyst Color Biotech Upgrades Price Target Analyst Ratings General Best of Benzinga

Latest Ratings

INTCJP MorganMaintains70.0
STMCanaccord GenuityMaintains47.0
ELDeutsche BankMaintains248.0
UAADeutsche BankMaintains13.0
INTCDeutsche BankMaintains55.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at